iSTAR Medical was selected to present the latest data for MINIjectTM, its minimally-invasive glaucoma surgery (MIGS) device, at the OIS Glaucoma Innovation Showcase on 21st October 2021 at 1:20PM EDT.
Michel Vanbrabant, CEO, will present newly available two year preliminary safety and efficacy results in ~50 patients from the STAR-I and STAR-II MINIjectTM trials. The results show a remarkable 39% reduction in intraocular pressure (IOP) at 2 years combined with a reduction in medication by about half. In addition, about half of patients remained medication-free.
“The studies show that MINIject consistently demonstrates powerful and sustained performance in primary open angle glaucoma patients across regions. We are looking forward to offering this safe and intuitive procedure with low post-operative patient management to surgeons before the end of the year, upon CE-Marking approval,” revealed Vanbrabant.
This virtual event will begin with a market overview followed by a showcase of several promising start-ups in the Glaucoma sector, and conclude with two deep-dive panel discussions. Throughout the event, you will be able to ask questions and network with other participants in real-time.
Registration is free: here